This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
Sanofi CEO Chris Viehbacher offers insight on quarterly earnings, his plans for the company going forward, growth in emerging markets, and the orphan drugs boom.
SHRINKING PROFIT: Sanofi saw its earnings slump in the third quarter as generic competitors ate into profits of its Eloxatin cancer treatment. DETAILS: Sanofi earned 1.6 billion for the July-September quarter, down 20 percent from 2 billion a year earlier.
TARRYTOWN, N.Y.-- Regeneron Pharmaceuticals Inc. on Wednesday reported third-quarter results that far exceeded Wall Street expectations as it won key new approvals for its eye drug Eylea and cancer drug Zaltrap.
NEW YORK-- Isis Pharmaceuticals Inc. said Tuesday that it will get $1.1 million from Alnylam Pharmaceuticals Inc. as part of Alnylam's new collaboration with Genzyme.
The FDA is not required to follow the committee's advice, though it often does. In its review posted ahead of the meeting, the FDA said Kynamro was linked to both benign and cancerous tumors. Jefferies analyst Eun Yang expects "very limited use of Kynamro if approved," due to the safety concerns brought up at the FDA meeting.
Drug developer Isis Pharmaceuticals Inc. and partner Genzyme said Thursday a panel of advisers to the Food and Drug Administration had voted 9 to 6 to recommend approval of Kynamro, for treating patients genetically predisposed to have sky-high LDL, or bad cholesterol. The FDA is not bound to follow recommendations of its advisers, but usually does so.
DRINK UP: The Coca-Cola Co. and drug maker Sanofi are partnering to launch a line of "beauty drinks" in France. SMALL TEST: Coca-Cola declined to give details but said in a statement that the drinks will be sold in a "small scale pilot" limited to a number of pharmacies in the country.
NEW YORK-- The Coca-Cola Co. and Sanofi are partnering to launch a line of "beauty drinks" in France. The Coca-Cola business unit in France said in a statement that the drinks will be sold in a "small scale pilot" limited to a number of pharmacies in the country.
NEW YORK-- Shares of Isis Pharmaceuticals Inc. skidded Tuesday as regulators raised questions about links between the company's experimental cholesterol drug Kynamro and cancer. THE SPARK: Isis and its partner Genzyme will discuss Kynamro with a Food and Drug Administration advisory panel on Thursday.
Oct 12- Watson Pharmaceuticals Inc:. *Watson's generic Avaproï¿ ½ receives FDA approval. *Irbesartan tablets USP is the generic equivalent to Sanofi's Avaproï¿ ½.
LYON, Oct 12- Sanofi's Genzyme unit has received positive feedback from U.S. doctors after the recent launch of multiple sclerosis pill Aubagio and moving toward refiling its FDA application for MS drug Lemtrada, senior executives said on Friday.
NEW YORK-- A Jefferies& Co. analyst said Thursday that sales of diabetes drugs should keep growing at a strong clip for the rest of the decade, reaching $65 billion a year in 2020.. He said Eli Lilly and Co. should surpass France's Sanofi as the second-largest diabetes drug seller.
LONDON, Oct 11- European equities were set to fall for a fourth straight session on Thursday, mirroring losses on Wall Street and in Asia, with concerns about weaker corporate earnings and global growth seen pushing shares towards one-month lows.
EDF Chief Executive Henri Proglio is expected to step down from French utility Veolia's board, French daily Les Echos reported. Europe's car market will not really recover without EU-led coordination of capacity cuts, Fiat and Chrysler Chief Executive Sergio Marchionne said, in an apparent back-track on comments he made at the Paris auto show last month.
PARIS, Oct 10- French drug maker Sanofi has dropped plans to exit its research laboratory in the southern town of Toulouse as part of a reorganisation of its French research operations, Industry Minister Arnaud Montebourg said on Wednesday.
Oct 9- Regulus Therapeutics Inc:. *Sanofi reports 10.99% passive stake in Regulus Therapeutics Inc as. of October 4- SEC filing* Source text:.
*FTSE 100 index finishes 0.5 percent lower. *Charts signal FTSE's uptrend intact. were down 0.4 percent after the World Bank cut its growth forecasts for China and as investors prepared for third-quarter earnings, which kick off on Tuesday in the United States with results from aluminium company Alcoa.
LONDON, Oct 8- Sanofi Pasteur MSD, the vaccine joint venture of Sanofi and Merck& Co, has recalled some batches of its typhoid vaccine because of concerns about effectiveness, Britain's drug regulator said on Monday.
PARIS, Oct 8- French drugmaker Sanofi said on Monday it will buy back certificates related to the success of Genzyme drugs for a total cost of about $70 million, representing $1.75 per contingent value right. Sanofi said last month it would buy back up to $152 million worth of the outstanding CVRs, which are linked to its 2011 purchase of U.S. biotech Genzyme.
ended slightly lower on Friday, breaking a four-session winning run, while the MSCI broad index of Asia Pacific shares outside Japan. on Tuesday, and after the World Bank cut its economic growth forecasts for the East Asia and Pacific region, warning about risks the slowdown in China could get worse and last longer than expected.